Lu AF28996

Lu AF28996 is a dual dopamine D 1 -like and D 2 -like receptor agonist which is under development for the treatment of Parkinson's disease.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Lu AF28996 is a dual dopamine D 1 -like and D 2 -like receptor agonist which is under development for the treatment of Parkinson's disease. It is taken orally. The drug is a prodrug that is reversibly converted into an active form.

Lu AF28996 was first described in the scientific literature by 2021. It is under development by Lundbeck. As of April 2025, the drug is in phase 1 clinical trials.

The chemical structure of Lu AF28996 does not yet appear to have been disclosed.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1358295260 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.